7
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Linfoma de Burkitt asociado a Virus de la Inmunodeficiencia Humana. Reporte de un caso clínico. Translated title: Burkitt lymphoma associated with Human Immunodeficiency Virus. A clinical case report.

      case-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          RESUMEN: El linfoma de Burkitt es un linfoma de células B maduras altamente agresivo, de baja incidencia. Según la Organización Mundial de la Salud presenta tres variantes: endémico, esporádico y asociado al Virus de la Inmunodeficiencia Humana. Este último representa el 30-40% de los linfomas no Hodgkin en pacientes seropositivos para virus de la inmunodeficiencia humana. El tratamiento con quimioterapia en combinación a terapia antirretroviral de gran actividad da muy buenos resultados. Se reporta caso de paciente seropositivo para virus de la inmunodeficiencia humana con linfoma de Burkitt en la cavidad oral, tratado con la terapia anteriormente mencionada.

          Translated abstract

          ABSTRACT: Burkitt lymphoma is a highly aggressive mature B-cell lymphoma with a low incidence. According to the World Health Organization, it has three variants: endemic, sporadic and associated with Human Immunodeficiency Virus (HIV). The last one represents 30-40% of non-Hodgkin’s lymphomas in HIV seropositive patients. Treatment with chemotherapy in combination with highly active antiretroviral therapy gives very good results. Here is the case report of a HIV seropositive patient who developed Burkitt lymphoma in the oral cavity and received this treatment.

          Related collections

          Most cited references10

          • Record: found
          • Abstract: found
          • Article: not found

          Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort.

          Overall survival (OS) of patients with acquired immunodeficiency syndrome (AIDS)-related Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) and plasmablastic lymphoma (PBL) was analysed in the German AIDS-related-Lymphoma-Cohort-Study. Of 291 patients prospectively included between January 2005 and December 2012, 154 had DLBCL, 103 BL and 34 PBL. Two-year OS rates were similar between BL (69%) and DLBCL patients (63%) but lower for PBL patients (43%). Intermediate (Hazard ratio [HR] 4·1 95% confidence interval [CI] 1·98-8·49) or high (HR 4·92 95% CI 2·1-11·61) International Prognostic Index, bone marrow involvement (HR 1·69 95% CI 1·00-2·84) and PBL histology (HR 2·24 95% CI 1·24-4·03) were independent predictors of mortality.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            HIV-associated lymphoma.

            The incidence of aggressive lymphoma in the setting of HIV infection is significantly increased relative to the general population. Combination antiretroviral therapy (cART) for HIV has reduced the incidence of these neoplasms and has significantly improved clinical outcome for those who do develop lymphoma and require chemotherapy. With the possible exception of those individuals with the most severe immunocompromise, patients with HIV-associated lymphoma can be treated with the same standard immuno-chemotherapy regimens used in the immunocompetent population with similar expectations for good clinical outcome. Infusional regimens like dose adjusted EPOCH-R appear to be highly effective first-line therapy and for relapsed patients high-dose chemotherapy with autologous stem cell support is well-tolerated and effective. However, it should be recognized that there are unique risks associated with management of lymphoma in this patient population. While opportunistic infections are no longer a significant cause of death, antiretroviral agents used for management of HIV infection may interact with chemotherapeutic agents and other adjunctive therapies making communication between the treating Oncologist and the patient's primary HIV treatment provider of prime importance. Copyright © 2012 Elsevier Ltd. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Treating Burkitt Lymphoma in Adults.

              Burkitt lymphoma is an uncommon form of aggressive lymphoma affecting approximately 1200 patients per year in the USA. It is characterized by a translocation involving the MYC oncogene. Three subtypes of Burkitt lymphoma are recognized: the endemic form, occurring primarily in Africa and associated with the Epstein-Barr virus (EBV); the sporadic form, representing less than 3 % of all non-Hodgkin lymphomas (NHL); and the immunodeficiency-associated form, occurring primarily in HIV-infected patients. Burkitt lymphoma appears histologically with a diffuse pattern of intermediate-sized monomorphic B cells, multiple nucleoli, a very high proliferative rate, and frequent mitotic figures. Recent advances in transcriptional profiling have improved the current molecular understanding of Burkitt lymphoma and have better characterized its mutational landscape. Most Burkitt lymphoma patients are cured with intensive treatment; however, prognosis is poor in elderly patients and those with relapsed disease.
                Bookmark

                Author and article information

                Contributors
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Journal
                piro
                Revista clínica de periodoncia, implantología y rehabilitación oral
                Rev. Clin. Periodoncia Implantol. Rehabil. Oral
                Sociedad de Periodoncia de Chile. Sociedad de Implantología Oral de Chile. Sociedad de Prótesis y Rehabilitación Oral de Chile. (Santiago, , Chile )
                0719-0107
                December 2019
                : 12
                : 3
                : 148-150
                Affiliations
                [3] Santiago orgnameHospital San José Chile
                [1] Santiago orgnameHospital San José Chile
                [2] Santiago Santiago de Chile orgnameUniversidad de Chile orgdiv1Facultad de Odontología Chile
                Article
                S0719-01072019000300148 S0719-0107(19)01200300148
                e957760b-ff45-4d1b-823e-63b242ba664e

                This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

                History
                : 11 December 2018
                : 05 August 2019
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 15, Pages: 3
                Product

                SciELO Chile

                Categories
                Reportes Clínicos

                Burkitt lymphoma,Human immunodeficiency virus,Drug therapy,Antiretroviral therapy, Highly active,Linfoma de Burkitt,Virus de la inmunodeficiencia humana,Terapia de drogas,Terapia antirretroviral,Altamente activa

                Comments

                Comment on this article